This study aims to collect real‑world information from people receiving standard radiotherapy for cancer. By looking at how radiotherapy is used in everyday clinical practice (not just in clinical trials) researchers hope to better understand how treatments work and how they can be improved for future patients.

Radiotherapy is an important part of cancer treatment for many people. Over the last 10 years, radiotherapy technology and techniques have changed quickly. However, these improvements are often introduced before their full impact on patients is formally assessed. Traditional clinical trials can be difficult to run for fast‑changing technologies and often do not include groups such as older patients or those with other health conditions.

What the study will look at

To understand how radiotherapy works in real‑world settings, this study will collect a wide range of information, including:

• Clinical details about your cancer and treatment
• Diagnostic scans and radiotherapy imaging
• Information about your radiotherapy plan and delivery
• Health‑related quality of life
• Health‑economic information (for example, how treatment affects use of healthcare services)

Patients may join different parts of the study, known as cohorts, each with its own aims. The information collected may help researchers:

• Identify patterns in how radiotherapy is used and what affects patient outcomes
• Understand how cancer and its treatment progress over time
• Develop standards of care for new radiotherapy techniques and technologies
• Build evidence to support new treatment methods
• Improve the quality and safety of radiotherapy across Europe
• Learn how radiotherapy affects patients’ daily lives and wellbeing
• Study the broader impact of radiotherapy on healthcare systems.
  
  

Who can take part

• The study is open to people aged 12 and over who are receiving radiotherapy for cancer
• It will run in the UK and several other countries
• There is no limit to the number of participants
• The study will continue as long as it remains scientifically useful, ethical, and practical. 
• Patient receiving radiotherapy for oligometastatic disease. 

Who is running the study

This research is a joint initiative from two major European organisations:

• The European Organisation for Research and Treatment of Cancer (EORTC)
• The European Society for Radiotherapy and Oncology (ESTRO)
  
  

Together, they aim to improve radiotherapy for current and future patients by learning from real‑world experiences.

Patients joining this study will be asked to consent to the researchers collecting and anonymising certain aspects of their clinical and treatment data. No extra appointments will be required and no questionnaires will be conducted.